Background Radioiodine ablation may be associated with improved survival in patients with
intermediate-risk follicular cell differentiated thyroid cancer (FCDTC). The aim of this study …

Objective To assess efficiency of various I-131 activities on thyroid remnant ablation in
thyroid cancer patients. The significance of patients' characteristics, pathologic features and …

Objective The efficacy of low-dose radioiodine therapy (RIT) for intermediate-risk or high-risk
differentiated thyroid cancer (DTC) patients is controversial. Because of the country's …

Objectives: To prospectively evaluate the outcome of patients with low-risk papillary thyroid
carcinoma treated with total thyroidectomy (TT) who did not undergo radioiodine remnant …

The aim of the study was to assess whether stimulation by recombinant human TSH (rhTSH)
may be used in patients with differentiated thyroid carcinoma for postsurgical ablation of …

Background: In December 2007, the USFDA approved recombinant human thyroid
stimulating hormone (rhTSH) for radioiodine remnant ablation after total thyroidectomy in …

Objective To evaluate the efficacy of recombinant human thyroid stimulating hormone
[rhTSH (versus hypothyroidism)] in thyroid ablation with an activity of 1.1 GBq (30 mCi) 131 I …

The aim of this study was to evaluate the efficacy of different radioactive iodine (I-131)
activities used for re-ablation, to compare various combinations of treatment activities, and to …

Radioiodine activity required for remnant thyroid ablation is of great concern, to avoid
unnecessary exposure to radiation and minimize adverse effects. We investigated clinical …

For several years now recombinant human TSH (rhTSH) has been approved by the
European Medicines Agency (EMEA) for the preparation of differentiated thyroid carcinoma …